This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXMPEA601E0_M.jpg
In its most recent earnings report, the company disappointed with earnings coming in at -$0.96, which was well below the consensus estimate of -$0.56. While earnings improved sequentially from the previous quarter, they were down year-over-year. The company also received disappointing news in May as the FDA won’t grant accelerated approval to its pipeline drug sparsentan.
The company does look good from a short-term debt perspective as it had $521 million in cash as of March, compared with no short-term debt. Unfortunately, its net profit margin is -113.2%. In terms of sales growth, the company has grown revenue an average of 10.4% per year over the past five years.
